Last updated: August 31, 2026
Clorazepate dipotassium is a mature, low-growth generic benzodiazepine market with limited brand economics, multiple suppliers, and minimal remaining intellectual-property protection. Revenue is driven by chronic and episodic prescriptions for anxiety, alcohol withdrawal, and adjunctive seizure management, but demand is constrained by controlled-substance regulation, dependence risk, substitution by newer therapies, and declining use of older benzodiazepines.
No reliable public source reports a standalone global revenue figure for clorazepate dipotassium. The product is sold primarily through generic channels, and company filings generally aggregate it with broader portfolios. Its financial profile is therefore best assessed through market structure, prescription volume, generic pricing, regulatory barriers, and manufacturer participation rather than a precise branded-sales estimate.
What is clorazepate dipotassium used for?
Clorazepate dipotassium is an oral benzodiazepine prodrug converted to desmethyldiazepam, also known as nordiazepam. U.S. labeling identifies three principal uses:
- Management of anxiety disorders.
- Relief of symptoms associated with acute alcohol withdrawal.
- Adjunctive therapy for partial seizures.
The drug is available in tablet form, historically under the Tranxene brand and currently through generic products. FDA labeling states that clorazepate is a Schedule IV controlled substance and carries risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions [1, 2].
Its long-acting metabolite supports dosing convenience but also creates a prolonged exposure profile. That characteristic can be useful in alcohol withdrawal and seizure-related treatment, while limiting its attractiveness for long-term anxiety treatment where clinicians increasingly favor antidepressants, psychotherapy, or shorter-duration benzodiazepine use.
How large is the clorazepate dipotassium market?
The clorazepate market is small relative to major benzodiazepine categories such as alprazolam, lorazepam, and diazepam. Public financial disclosures do not separately identify clorazepate revenue for most manufacturers.
Market structure
| Market characteristic |
Clorazepate dipotassium position |
| Product type |
Mature small-molecule generic |
| Primary dosage form |
Oral tablets |
| U.S. brand |
Tranxene |
| Prescription status |
Controlled prescription drug |
| DEA classification |
Schedule IV |
| Key indications |
Anxiety, alcohol withdrawal, adjunctive seizure therapy |
| Patent position |
Legacy protection expired; market is generic |
| Biosimilar exposure |
None |
| Main commercial constraint |
Low unit value and limited prescription growth |
| Main regulatory constraint |
Controlled-substance and benzodiazepine safety requirements |
The economic value is concentrated in manufacturing scale, supply reliability, wholesaler access, and portfolio efficiency. A company with an existing generic infrastructure can sell clorazepate as a niche portfolio product even when the molecule alone produces modest revenue.
Prescription and demand drivers
Demand is shaped by several factors:
- Continued use in patients stabilized on long-acting benzodiazepines.
- Treatment of alcohol withdrawal in outpatient and institutional settings.
- Adjunctive seizure treatment when clinicians select an established benzodiazepine prodrug.
- Generic substitution and payer formulary placement.
- Availability of competing benzodiazepines and nonbenzodiazepine treatments.
Demand is structurally mature. Growth is more likely to come from temporary supply disruptions, competitor exits, or pricing changes than from expansion of the treated population.
What is the financial trajectory for clorazepate dipotassium?
Clorazepate has followed the standard financial trajectory of an established generic drug:
- Brand-period revenue was historically supported by product recognition and limited competition.
- Patent expiry shifted the market to generic pricing.
- Additional generic entrants reduced average selling prices.
- Revenue became dependent on volume, supply continuity, and manufacturing cost.
- Current commercial value is likely stable to declining in nominal terms, with intermittent price volatility when suppliers leave the market.
The product does not have the commercial characteristics of a high-growth pharmaceutical asset. It lacks new-chemical-entity exclusivity, a premium specialty indication, a differentiated delivery system, or a large protected population.
Revenue exposure for manufacturers
For diversified generic companies, clorazepate revenue is likely immaterial at group level. Its value may still be meaningful at product level when:
- Few suppliers remain active.
- The product has difficult procurement or limited API availability.
- A manufacturer holds a reliable institutional or wholesaler customer base.
- Competitors experience manufacturing interruptions.
- The product is bundled with other CNS generics in contracting negotiations.
A company-specific revenue estimate cannot be derived from public annual reports because manufacturers generally combine clorazepate with broader U.S. generic, CNS, or legacy-product categories.
When did clorazepate lose exclusivity?
Clorazepate lost meaningful market exclusivity decades ago. Tranxene was approved in the United States in the 1970s, and generic clorazepate products have been marketed for many years. The current market is therefore post-exclusivity and price-competitive.
The relevant commercial conclusion is not a future patent cliff. It is the absence of a material remaining exclusivity event.
| Exclusivity element |
Current commercial effect |
| New chemical entity exclusivity |
Expired |
| Orphan-drug exclusivity |
Not applicable |
| Pediatric exclusivity |
No material current effect |
| Market exclusivity |
Expired |
| Patent-based generic barrier |
No material current barrier identified |
| Biosimilar exclusivity |
Not applicable |
What patents protect clorazepate dipotassium?
No commercially significant unexpired composition-of-matter patent is associated with clorazepate dipotassium. The molecule is an old benzodiazepine, and generic manufacturers have long marketed the active ingredient.
Formulation patents
The commercial product is an immediate-release oral tablet with no widely recognized modern formulation platform. There is no established extended-release, transdermal, implantable, depot, or abuse-deterrent clorazepate product generating a material patent moat.
Any historical formulation or manufacturing patents would not prevent routine generic competition today. The competitive advantage is operational rather than patent-based.
Method-of-use patents
The approved uses, including anxiety, alcohol withdrawal, and adjunctive seizure treatment, are longstanding indications. No active method-of-use patent is known to create a meaningful barrier to generic prescribing or substitution.
What is the FDA regulatory status of clorazepate?
FDA-approved clorazepate products remain prescription medicines subject to controlled-substance requirements. The FDA-approved labeling covers tablets in multiple strengths, including 3.75 mg, 7.5 mg, and 15 mg products, depending on the manufacturer and product presentation [1, 2].
The main regulatory event affecting the category was FDA’s 2020 class-wide update to benzodiazepine labeling. The changes added or strengthened warnings concerning abuse, misuse, addiction, physical dependence, and withdrawal reactions [3].
These warnings increase prescriber and patient scrutiny. They do not remove clorazepate from the market, but they make long-term use more difficult to expand.
FDA approval pathway
Generic clorazepate products are generally approved through abbreviated new drug applications. The relevant regulatory requirements include:
- Pharmaceutical equivalence to the reference product.
- Bioequivalence.
- Manufacturing compliance.
- Controlled-substance handling requirements.
- Labeling consistent with FDA benzodiazepine warnings.
Because the product is an established oral tablet, the development burden is materially lower than for a new CNS drug. The principal development risks are manufacturing validation, bioequivalence execution, API sourcing, and commercial justification.
What is the Orange Book status of clorazepate?
Clorazepate products are represented in FDA’s approved-drug databases through the reference product and abbreviated new drug applications. The market is dominated by generic approvals rather than active brand exclusivity.
The Orange Book is relevant for confirming reference-listed-drug status, therapeutic equivalence codes, and any listed patent or exclusivity information. For clorazepate, the strategic conclusion is that Orange Book-listed exclusivity does not create a material barrier to generic entry or substitution [4].
An applicant considering a new clorazepate product would generally face a generic competition analysis, not a Paragraph IV patent litigation analysis.
Which companies compete in the clorazepate market?
Competition has historically included large generic manufacturers and smaller specialty suppliers. Product availability can vary by strength, package size, manufacturer, wholesaler, and country.
Known or historically associated generic channels include companies such as:
- Teva Pharmaceuticals.
- Mylan, now part of Viatris.
- Par Pharmaceutical.
- Rising Pharma.
- Heritage Pharmaceuticals.
- Other approved generic manufacturers and labelers.
The exact active supplier set changes over time. FDA approval does not guarantee current commercial distribution, and a labeler may retain an approved product while selling limited quantities or none at all.
Competitive positioning
| Competitive factor |
Impact on clorazepate |
| Number of approved ANDAs |
Supports generic substitution |
| Active commercial suppliers |
Determines near-term price pressure |
| API availability |
Can create temporary shortages |
| Tablet strengths |
Affects portfolio completeness |
| Controlled-substance infrastructure |
Raises operational requirements |
| Institutional contracts |
Can support stable volume |
| Retail reimbursement |
Compresses margins |
The strongest commercial position belongs to suppliers that maintain consistent inventory and can support controlled-substance compliance across the supply chain.
Are there Paragraph IV challenges or generic launch risks?
Paragraph IV litigation is not a central current risk for clorazepate because the product’s principal patent and exclusivity periods expired long ago. Generic launch risk instead comes from economics and execution.
Generic entry risks
A new entrant would face the following risks:
- Low average selling prices.
- Established generic substitution.
- Limited market expansion.
- Potentially modest annual prescription volume.
- Distributor and pharmacy contracting barriers.
- API and finished-dose manufacturing costs.
- Controlled-substance registration and inventory controls.
- Risk that competitors respond with aggressive pricing.
The absence of patent barriers makes regulatory approval more predictable, but it also removes the ability to earn a premium during a protected launch period.
Generic launch scenarios
| Scenario |
Likely market effect |
| New entrant launches into a multi-supplier market |
Price erosion and limited share capture |
| One or more suppliers exit |
Temporary price and availability improvement |
| Shortage or API disruption occurs |
Volatility in wholesale acquisition cost |
| Large buyer awards a supply contract |
Stable volume but compressed margin |
| Prescribing shifts toward alternatives |
Long-term volume decline |
| New formulation gains approval |
Potential niche differentiation |
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers are moderate but not technologically severe. Clorazepate is a conventional oral solid dosage product, so the formulation is comparatively accessible to experienced generic manufacturers.
The main barriers are:
- Qualified clorazepate API supply.
- Controlled-substance security and recordkeeping.
- Scale-efficient tablet production.
- Stability and dissolution performance.
- Consistent supply across multiple strengths.
- Regulatory inspection readiness.
- Low-margin economics.
The API itself is a more relevant operational issue than patent protection. A supplier that cannot achieve sufficient scale may find the product commercially unattractive even after receiving FDA approval.
How does clorazepate compare with competing benzodiazepines?
Clorazepate competes with diazepam, lorazepam, alprazolam, clonazepam, and chlordiazepoxide. Its long-acting metabolite gives it a different pharmacokinetic profile from shorter-acting agents.
| Drug |
Typical commercial position |
Relative clorazepate implication |
| Alprazolam |
High-volume anxiety treatment |
Stronger brand familiarity and historical demand |
| Lorazepam |
Anxiety, procedural use, alcohol withdrawal |
Broad institutional and acute-care use |
| Diazepam |
Anxiety, muscle spasm, seizures, withdrawal |
Broad indication and long market history |
| Chlordiazepoxide |
Alcohol withdrawal and anxiety |
Direct competitor in withdrawal management |
| Clonazepam |
Seizures and panic disorder |
Stronger chronic CNS positioning |
| Clorazepate |
Anxiety, alcohol withdrawal, adjunctive seizures |
Smaller and more specialized demand |
Clorazepate’s long duration can support adherence and withdrawal-management use, but it also exposes the product to concerns about accumulation, sedation, dependence, and prolonged withdrawal.
What litigation and settlement agreements affect clorazepate?
No major current patent litigation or settlement agreement is central to the clorazepate market. The product’s commercial status is defined by long-expired exclusivity and generic availability rather than an active patent dispute.
Potential legal exposure is more likely to arise from:
- Controlled-substance compliance.
- Product liability.
- Labeling and warning adequacy.
- Manufacturing quality.
- Distribution controls.
- Diversion and suspicious-order monitoring.
These issues affect operating cost and compliance risk, but they do not create a conventional branded-generic litigation framework.
Is there biosimilar risk for clorazepate?
No. Biosimilars apply to biologic products, while clorazepate is a chemically synthesized small molecule. Competitive risk comes from conventional generic tablets, therapeutic substitution, and changes in benzodiazepine prescribing.
What is the geographic coverage of clorazepate?
Clorazepate has a long history of use in the United States and other markets, but product names, strengths, regulatory classifications, and commercial availability vary by country. The United States market is shaped by DEA Schedule IV controls, FDA approval, state prescribing rules, and pharmacy distribution.
International demand is influenced by:
- National reimbursement policies.
- Local benzodiazepine restrictions.
- Availability of diazepam and chlordiazepoxide.
- Generic manufacturing concentration.
- Hospital and retail procurement.
- Local controlled-drug regulations.
The United States is likely the most commercially transparent market because FDA approval and Orange Book data identify approved products and reference-drug relationships.
What is the investment outlook for clorazepate dipotassium?
Clorazepate is a defensive legacy generic rather than a growth asset. Its investment value depends on portfolio fit.
Positive factors
- Low clinical development risk.
- Longstanding physician familiarity.
- Established generic demand.
- Potential supply-driven pricing opportunities.
- Limited likelihood of new branded competition.
Negative factors
- No meaningful patent moat.
- Small addressable market.
- Controlled-substance compliance burden.
- Substitution by competing benzodiazepines and nonbenzodiazepine treatments.
- Low pricing power.
- Declining long-term benzodiazepine utilization in some treatment settings.
- Limited ability to create value through formulation innovation.
A manufacturer may rationally retain clorazepate as part of a broader CNS portfolio, but a standalone acquisition thesis would require evidence of supplier scarcity, durable institutional contracts, or an identifiable manufacturing advantage.
Key Takeaways
- Clorazepate dipotassium is a mature generic benzodiazepine with no meaningful remaining market exclusivity.
- The U.S. product is associated with Tranxene and multiple generic manufacturers.
- Public filings do not provide a reliable standalone global revenue figure.
- Financial performance is driven by volume, supplier count, manufacturing cost, and occasional supply disruption.
- Paragraph IV litigation and patent settlements are not major current market factors.
- FDA’s 2020 benzodiazepine labeling changes increased safety and dependence warnings.
- The principal competitive risks are therapeutic substitution, controlled-substance restrictions, and low generic pricing.
- The product has no biosimilar exposure.
- Its best commercial use is as a portfolio product for an established generic manufacturer with efficient CNS distribution.
FAQs
Does clorazepate dipotassium have a future patent cliff?
No major future patent cliff is expected. Its principal exclusivity periods expired decades ago, and the product is already exposed to generic competition.
Can a new company launch a generic clorazepate tablet?
Yes. A manufacturer could pursue an abbreviated new drug application if it satisfies FDA pharmaceutical-equivalence, bioequivalence, quality, and controlled-substance requirements. Commercial viability would depend on market size and supplier competition.
Is clorazepate more profitable than diazepam?
Not on a molecule-wide basis. Diazepam has broader indications and generally stronger market recognition. Clorazepate may become temporarily more profitable if competing suppliers exit or supply disruptions reduce availability.
Is clorazepate included in U.S. benzodiazepine safety warnings?
Yes. FDA’s class-wide benzodiazepine labeling changes apply to clorazepate and address abuse, misuse, addiction, physical dependence, and withdrawal reactions.
What would most improve clorazepate’s commercial value?
The strongest potential value drivers are a supply-constrained market, reliable API access, institutional contracting, a differentiated formulation, or a broader CNS portfolio that lowers distribution and compliance costs.
References
-
U.S. Food and Drug Administration. (2023). Clorazepate dipotassium tablets: Prescribing information. FDA-approved labeling.
-
DailyMed. (2024). Clorazepate dipotassium tablet. U.S. National Library of Medicine.
-
U.S. Food and Drug Administration. (2020). FDA requiring boxed warning updated to improve safe use of benzodiazepine drug class. https://www.fda.gov
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov
-
U.S. Drug Enforcement Administration. (2024). Drug scheduling. https://www.dea.gov
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/
